类风湿关节炎达标低疾病活动度后停用托法替布的观察研究
这项多中心、非随机、开放、前瞻性观察研究纳入64例经托法替布治疗达低疾病活动度的RA患者,54例停药、10例继续用药;停药后52周37%(20/54)的患者无复发维持停药,基线RF滴度较低者更易维持停药。未能维持者重启托法替布或其他生物制剂后疾病活动改善。
要点
- RA达LDA后约三分之一患者可停用托法替布且52周无复发。
- 基线RF滴度较低者停药后更易维持无药缓解。
- 停药失败者重启托法替布或其他生物制剂可改善病情。
核心结论
- 约三分之一的RA患者在托法替布治疗达LDA后停药可维持无复发。
- 低RF滴度可预测停用托法替布后维持LDA。
研究设计与样本
- 多中心、非随机、开放、前瞻性观察研究,纳入64例托法替布治疗后达LDA的RA患者。
- 停药或继续治疗由医患共同决策确定,主要终点为治疗后第52周仍无托法替布的比例。
- 对第52周前未能停药者采用末次观测值结转法。
主要发现
- 64例中54例停药、10例继续托法替布治疗。
- 第52周停药组20/54例(37%)仍无托法替布且无疾病复发。
- 第52周停药组疾病活动度高于继续治疗组。
- 停药组中维持无托法替布者基线RF滴度显著低于未维持者(40 vs 113 U/ml)。
- 未能维持无托法替布状态者重启托法替布或其他生物制剂后疾病活动改善。
关键数值与推荐
- 第52周仍无托法替布且无复发的比例为37%(20/54)。
- 维持无托法替布者基线RF滴度为40 U/ml,未维持者为113 U/ml。
临床怎么用
- 对托法替布治疗达LDA的RA患者,可考虑在医患共同决策下尝试停药。
- 基线RF滴度较低者更支持尝试停用托法替布。
- 停药后需监测疾病活动,复发时重启托法替布或其他生物制剂可改善病情。
局限性
- 研究为非随机、开放设计,停药与继续治疗由医患决策决定,可能存在选择偏倚。
- 样本量较小(64例),停药组54例、继续组10例。
- 对第52周前未能停药者采用末次观测值结转法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether tofacitinib can be discontinued in patients with RA who achieve low disease activity (LDA). METHODS: RA patients with LDA after tofacitinib treatment in a phase III and long-term extension study were enrolled in this multicentre, non-randomized, open, prospective, observational study. The decision of discontinuation or continuation of tofacitinib was determined based on patient-physician decision making with informed consent. The primary endpoint was the proportion of patients who remained tofacitinib-free at post-treatment week 52. Clinical outcome was compared between those who continued and those who discontinued tofacitinib. The last observation carried forward method was used for patients who could not discontinue tofacitinib before week 52. RESULTS: Of 64 patients, 54 discontinued and 10 continued tofacitinib therapy. At post-treatment week 52, 20 of the 54 patients (37%) of the discontinuation group remained tofacitinib-free without disease flare. Disease activity at post-treatment week 52 was higher in the discontinuation group than the continuation group. Among the discontinuation group, the RF titre at baseline was significantly lower in patients who remained tofacitinib-free than those who did not (40 vs 113 U/ml). In fact, a higher proportion of patients with lower RF remained tofacitinib-free at week 52 compared with those with higher RF at baseline. In patients who could not achieve tofacitinib-free status, re-initiation of tofacitinib or other biologics improved disease activity. CONCLUSION: It is possible to discontinue tofacitinib without flare in about a third of patients with RA. A low RF predicts maintenance of LDA after discontinuation of tofacitinib.
引用
- Kubo S, Yamaoka K, Amano K, et al. Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. Rheumatology (Oxford). 2017. PMID: 28407099. doi:10.1093/rheumatology/kex068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。